---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-257205"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:03:05.910864+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Taysha Q3 net loss $25.5M; TSHA-102 high dose safe; FDA aligns on pivotal trial design

## Summary
- Net loss $25.5M ($0.10/sh) vs $117.1M loss in Q3 2023; cash $157.7M into Q4 2026.
- High dose TSHA-102 well tolerated; no SAEs or DLTs in 2 adolescent/adult and 1 pediatric patient.
- FDA aligned on trial design, endpoints, and natural history dataset for Part B of REVEAL trials.
- FDA approved pivotal TSHA-102 product manufactured with final commercial manufacturing process for REVEAL trials.
- Safety and efficacy data from high dose cohorts of both REVEAL trials expected H1 2025.

## SEC filing metadata
- accession: 0001193125-24-257205
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312524257205/0001193125-24-257205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312524257205/d877348d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-257205
- JSON: https://secwatch.observer/filing/0001193125-24-257205.json
- Plain text: https://secwatch.observer/filing/0001193125-24-257205.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.